TEMPE, Ariz., Dec. 10, 2008 (GLOBE NEWSWIRE) -- Capstone Therapeutics (NasdaqGM:CAPS - News) announced today positive safety results were obtained in the second of two planned Phase 1 human clinical trials of AZX100 in dermal / hypertrophic scarring. No serious treatment-emergent adverse events were reported in any subject. Secondary outcomes indicated a statistically significant signal of pharmacological effect in favor of AZX100. The secondary parameters were included in this study for the purpose of evaluating efficacy measurements for future clinical trials.
